BPG is committed to discovery and dissemination of knowledge
Articles in Press
6/12/2026 6:13:28 AM | Browse: 5 | Download: 0
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 121282
DOI 10.4251/wjgo.121282
Country China
Category Medicine, Research & Experimental
Manuscript Type Basic Study
Article Title Targeting cyclin-dependent kinase 6 partially reverses drug resistance in ripretinib-resistant gastrointestinal stromal tumor cells in vitro
Manuscript Source Unsolicited Manuscript
All Author List Xiao-Dong Wang, Chun-Hui Shou, Sheng-Chuan Chen, Yan-Yun Hong, Kan-Kai Zhu, Wei-Li Yang and Ji-Ren Yu
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China 82001695
Beijing Xisike Clinical Oncology Research Foundation Y-zai2021/ms-0133
Corresponding Author Ji-Ren Yu, Associate Chief Physician, Associate Research Scientist, Director, MD, PhD, Researcher, Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310000, Zhejiang Province, China. yujr0909@zju.edu.cn
Key Words Combination therapy; Apoptosis; Drug resistance; Protein kinase B signaling pathway; Cyclin-dependent kinase 6; Ripretinib; Gastrointestinal stromal tumor
Core Tip This study identifies cyclin-dependent kinase 6 (CDK6) as a key mediator of ripretinib resistance in gastrointestinal stromal tumors (GIST), with its overexpression driven by protein kinase B hyperactivation. CDK6 inhibitor induces G1-phase cell cycle arrest and apoptosis in ripretinib-resistant GIST cells, and combining CDK6 inhibitor palbociclib with ripretinib exerts a synergistic effect to reverse resistance, restoring the tumor cells’ sensitivity to ripretinib. This uncovers the protein kinase B/CDK6 axis as a novel target for treating ripretinib-resistant GIST, providing a new precision therapy strategy.
Citation Wang XD, Shou CH, Chen SC, Hong YY, Zhu KK, Yang WL, Yu JR. Targeting cyclin-dependent kinase 6 partially reverses drug resistance in ripretinib-resistant gastrointestinal stromal tumor cells in vitro. World J Gastrointest Oncol 2026; In press
Received
2026-03-23 06:48
Peer-Review Started
2026-03-23 06:48
First Decision by Editorial Office Director
2026-04-16 07:48
Return for Revision
2026-04-17 01:34
Revised
2026-05-11 00:40
Publication Fee Transferred
2026-05-21 01:43
Second Decision by Editor
2026-06-12 02:34
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-06-12 06:13
Articles in Press
2026-06-12 06:13
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com